Subscribe To

Price Alert Latest News Economic Calendar News

NVRO / Nevro Corporation (NVRO) Q4 2022 Earnings Call Transcript

Nevro Corporation (NYSE:NVRO ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, CEO and President Rod MacLeod - Chief Financial Officer Conference Call Participants Joanne Wuensch - Citibank Chris Pasquale - Nephron Vik Chopra - Wells Fargo Brandon Vazquez - William Blair Robbie Marcus - J.P. Morgan Dave Rescott - Truist Securities Simran Kaur - Piper Sandler Operator Good afternoon. Read More

Demo Live Account See Partner Details

Content Topics

Nevro

Corporation

NVRO

2022

Earnings

Call

Transcript

nvro

Stock

Posted: Feb 16 2023, 22:07

Author Name: Seeking Alpha

NVRO News

By Seeking Alpha
September 1, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic

By Zacks Investment Research
August 15, 2023

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.

By The Motley Fool
August 2, 2023

Why Shares of Nevro Are Down Wednesday

Nevro said it expects third-quarter revenue to fall between 4% to 6% year over year. The company is reorganizing its sales force.

By Seeking Alpha
August 1, 2023

Nevro Corp. (NVRO) Q2 2023 Earnings Call Transcript

Nevro Corp. (NYSE:NVRO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group LLC Kevin Th

By Zacks Investment Research
August 1, 2023

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

Nevro (NVRO) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.71

By Zacks Investment Research
June 19, 2023

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

By Seeking Alpha
May 9, 2023

Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued

Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficie

By Zacks Investment Research
April 27, 2023

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.